Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.44
NBY's Cash to Debt is ranked lower than
76% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. NBY: 1.44 )
Ranked among companies with meaningful Cash to Debt only.
NBY' s Cash to Debt Range Over the Past 10 Years
Min: 1.44  Med: 9999.50 Max: No Debt
Current: 1.44
Equity to Asset -1.00
NBY's Equity to Asset is ranked lower than
98% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NBY: -1.00 )
Ranked among companies with meaningful Equity to Asset only.
NBY' s Equity to Asset Range Over the Past 10 Years
Min: -1  Med: 0.56 Max: 0.76
Current: -1
-1
0.76
Interest Coverage N/A
NBY's Interest Coverage is ranked lower than
54% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NBY: N/A )
Ranked among companies with meaningful Interest Coverage only.
NBY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: N/A
N/A
9999.99
F-Score: 3
Z-Score: -35.51
M-Score: -2.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -479.66
NBY's Operating margin (%) is ranked lower than
72% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. NBY: -479.66 )
Ranked among companies with meaningful Operating margin (%) only.
NBY' s Operating margin (%) Range Over the Past 10 Years
Min: -1601.33  Med: -123.10 Max: 17.47
Current: -479.66
-1601.33
17.47
Net-margin (%) -433.07
NBY's Net-margin (%) is ranked lower than
71% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. NBY: -433.07 )
Ranked among companies with meaningful Net-margin (%) only.
NBY' s Net-margin (%) Range Over the Past 10 Years
Min: -1441.56  Med: -110.93 Max: 17.2
Current: -433.07
-1441.56
17.2
ROE (%) -2353.97
NBY's ROE (%) is ranked lower than
99% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. NBY: -2353.97 )
Ranked among companies with meaningful ROE (%) only.
NBY' s ROE (%) Range Over the Past 10 Years
Min: -293.21  Med: -66.94 Max: 26.07
Current: -2353.97
-293.21
26.07
ROA (%) -252.08
NBY's ROA (%) is ranked lower than
95% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. NBY: -252.08 )
Ranked among companies with meaningful ROA (%) only.
NBY' s ROA (%) Range Over the Past 10 Years
Min: -300.82  Med: -41.38 Max: 17.13
Current: -252.08
-300.82
17.13
ROC (Joel Greenblatt) (%) -5325.39
NBY's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. NBY: -5325.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NBY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5057.52  Med: -729.34 Max: 139.97
Current: -5325.39
-5057.52
139.97
Revenue Growth (3Y)(%) -35.60
NBY's Revenue Growth (3Y)(%) is ranked lower than
82% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NBY: -35.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NBY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -35.60 Max: 36.3
Current: -35.6
0
36.3
EBITDA Growth (3Y)(%) 3.50
NBY's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. NBY: 3.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NBY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.9  Med: 3.50 Max: 39.2
Current: 3.5
-34.9
39.2
EPS Growth (3Y)(%) 4.50
NBY's EPS Growth (3Y)(%) is ranked higher than
61% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NBY: 4.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NBY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.5  Med: 4.50 Max: 35.5
Current: 4.5
-32.5
35.5
» NBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

NBY Guru Trades in Q1 2015

Jim Simons 270,800 sh (+42.60%)
» More
Q2 2015

NBY Guru Trades in Q2 2015

Jim Simons 249,500 sh (-7.87%)
» More
Q3 2015

NBY Guru Trades in Q3 2015

Jim Simons 212,800 sh (-14.71%)
» More
Q4 2015

NBY Guru Trades in Q4 2015

Jim Simons 19,924 sh (-90.64%)
» More
» Details

Insider Trades

Latest Guru Trades with NBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 1.80
NBY's P/S is ranked higher than
88% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. NBY: 1.80 )
Ranked among companies with meaningful P/S only.
NBY' s P/S Range Over the Past 10 Years
Min: 1.1  Med: 4.71 Max: 34.44
Current: 1.8
1.1
34.44
Current Ratio 0.98
NBY's Current Ratio is ranked lower than
90% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. NBY: 0.98 )
Ranked among companies with meaningful Current Ratio only.
NBY' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 4.08 Max: 10.63
Current: 0.98
0.98
10.63
Quick Ratio 0.69
NBY's Quick Ratio is ranked lower than
91% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. NBY: 0.69 )
Ranked among companies with meaningful Quick Ratio only.
NBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 4.06 Max: 10.63
Current: 0.69
0.69
10.63
Days Inventory 312.20
NBY's Days Inventory is ranked lower than
85% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. NBY: 312.20 )
Ranked among companies with meaningful Days Inventory only.
NBY' s Days Inventory Range Over the Past 10 Years
Min: 104.77  Med: 221.93 Max: 270.06
Current: 312.2
104.77
270.06
Days Sales Outstanding 44.66
NBY's Days Sales Outstanding is ranked higher than
68% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. NBY: 44.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
NBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.1  Med: 49.55 Max: 94.54
Current: 44.66
0.1
94.54
Days Payable 718.71
NBY's Days Payable is ranked higher than
97% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. NBY: 718.71 )
Ranked among companies with meaningful Days Payable only.
NBY' s Days Payable Range Over the Past 10 Years
Min: 718.71  Med: 1400.67 Max: 3771.67
Current: 718.71
718.71
3771.67

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.42
NBY's Price/Median PS Value is ranked higher than
85% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. NBY: 0.42 )
Ranked among companies with meaningful Price/Median PS Value only.
NBY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 0.84 Max: 6.15
Current: 0.42
0.27
6.15
Price/Graham Number 0.20
NBY's Price/Graham Number is ranked higher than
96% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. NBY: 0.20 )
Ranked among companies with meaningful Price/Graham Number only.
NBY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.13  Med: 0.91 Max: 1.68
Current: 0.2
0.13
1.68
Earnings Yield (Greenblatt) (%) -151.93
NBY's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. NBY: -151.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NBY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 3.80 Max: 7.9
Current: -151.93
1.2
7.9

More Statistics

Revenue(Mil) $4
EPS $ -7.01
Beta-0.60
Short Percentage of Float4.73%
52-Week Range $1.63 - 26.25
Shares Outstanding(Mil)5.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 7 9 11
EPS($) -2.66 -2.83 -1.30
EPS without NRI($) -2.66 -2.83 -1.30

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PVOTF, OTCPK:BSEM, OSTO:KARE, NAS:WINT, OTCPK:EMBT, ASX:IMC » details
NovaBay Pharmaceuticals Inc was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc., and subsequently changed its name to NovaBay Pharmaceuticals, Inc. In June 2010, the Company was reincorporated under the laws of the state of Delaware. The Company is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with two distinct product categories, Aganocides, for the eye care market, NeutroPhase, for wound care, and CelleRx for the dermatology market; and clinical stage Aganocide Compounds. The Company is focusing its Aganocide compounds into three large therapeutic markets: Urology - Statistically- significant and clinically-meaningful results from a Phase 2 clinical study of Auriclosene Irrigation Solution to reduce urinary catheter blockage and encrustation, Ophthalmology - NovaBay is developing an eye drop formulation of auriclosene (NVC-422) for treating adenoviral conjunctivitis, for which there is currently no FDA-approved treatment, Dermatology - Partnered with Galderma, a dermatology company, the Company is developing a gel formulation of auriclosene (NVC-422) for treating impetigo, a contagious skin infection. The Company has also developed NeutroPhase, a distinct class of molecule from the Aganocides. NeutroPhase is an FDA 510(k)-cleared Advanced Skin and Wound Cleanser. It has developed variations of the NeutroPhase product such as i-Lid Cleanser and CelleRx. The competitors for its Aganocides and for NeutroPhase include large and small pharmaceutical and medical device companies, such as Pfizer, Inc., Johnson & Johnson, Abbott Grp. Plc., GlaxoSmithKline Plc, Sanofi-Aventis SA, Novartis AG, Smith & Nephew Plc, C.R. Bard, Molnlycke, Lohman and Roucher, Johnson and Johnson, 3M, Puricore and Oculus Innovative Sciences. The Company's Aganocide product candidate, auriclosene (NVC-422), as well as many of the product candidates they expect to develop in the future. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of its product candidates are subject to extensive regulation by the FDA, state agencies and comparable regulatory authorities in other countries.
» More Articles for NBY

Headlines

Articles On GuruFocus.com
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
[$$] NovaBay Not Seen Breaking Even for Years Apr 07 2016
NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two-Tranche Private Placement Apr 06 2016
NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two-Tranche Private Placement Apr 06 2016
NovaBay Pharmaceuticals Announces Filing of Annual Report on Form 10-K Mar 22 2016
NovaBay Pharmaceuticals Announces Filing of Annual Report on Form 10-K Mar 22 2016
NovaBay Pharmaceuticals to Present at 28th Annual ROTH Conference Mar 08 2016
NovaBay Pharma downgraded by Maxim Group Mar 07 2016
NovaBay Pharmaceuticals Reports 2015 Fourth Quarter and Full Year Financial Results Mar 03 2016
NovaBay Pharmaceuticals to Hold 2015 Fourth Quarter and Full Year Conference Call on March 3 Feb 25 2016
NovaBay Pharmaceuticals Announces $2.83 Million Private Placement Feb 24 2016
NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million Jan 11 2016
NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million Jan 11 2016
3 Biotech Stocks Under $10 to Trade for Big Breakouts Jan 08 2016
NovaBay Pharmaceuticals Secures $3 Million Bridge Loan Jan 07 2016
NovaBay Pharmaceuticals Secures $3 Million Bridge Loan Jan 07 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Dec 21 2015
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Dec 14 2015
NovaBay Declares Reverse Stock Split Dec 11 2015
NovaBay Declares Reverse Stock Split Dec 11 2015
NOVABAY PHARMACEUTICALS, INC. Financials Dec 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK